A cancer patient in Athens has received the first administration of a new lymphoma drug anywhere in Europe, and the resu...

A cancer patient in Athens has received the first administration of a new lymphoma drug anywhere in Europe, and the results came fast. The treatment, Denileukin diftitox-cxdl, was administered at the Agios Savvas General Anticancer Hospital in Athens. The patient is a middle-aged woman with advanced, treatment-resistant cutaneous T-cell lymphoma, a rare and aggressive skin cancer. She had already exhausted ten previous lines of treatment before this one. Her condition had deteriorated to the point where large, tumor-like skin lesions had severely reduced her ability to move and function in daily life. Doctors from two hospitals coordinated the case. Her initial diagnosis came from the dermatology clinic at Andreas Syggros Hospital, and the hematology team at Agios Savvas took over to administer the new therapy. After just four intravenous infusions in the first treatment cycle, doctors reported a rapid and significant clinical response. Her skin lesions have visibly receded, her physical condition has improved, and her quality of life has measurably increased. The response has now opened the door to the next step. Doctors are planning an allogeneic stem cell transplant from an unrelated donor, which will be carried out at Attikon University Hospital, with the goal of achieving long-term disease-free survival. Denileukin diftitox-cxdl is described as the first new systemic treatment option for relapsed or refractory cutaneous T-cell lymphomas in many years, according to an announcement from the 1st Regional Health Authority. Greece becoming the site of Europe's first administration puts Agios Savvas at the front of a treatment category where options have historically been very limited. #Greece #Cancer #MedicalBreakthrough